Imperial College London

ProfessorRohiniSharma

Faculty of MedicineDepartment of Surgery & Cancer

Professor Clinical Pharmacology and Medical Oncology
 
 
 
//

Contact

 

+44 (0)20 3313 3059r.sharma Website

 
 
//

Location

 

ICTEM buildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Lo:2021:10.2217/fon-2021-0697,
author = {Lo, SH and Sharma, R and Costentin, CE and Aggio, D and Shergill, S and Colaone, F and Brennan, VK and Straccia, VA and Agirrezabal, I and Lloyd, AJ},
doi = {10.2217/fon-2021-0697},
journal = {Future Oncology},
pages = {4275--4287},
title = {Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study},
url = {http://dx.doi.org/10.2217/fon-2021-0697},
volume = {17},
year = {2021}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AB - The present study aimed to explore patient preferences for attributes of advanced hepatocellular carcinoma (HCC) treatments. A stated preference survey was completed by 150 patients with HCC living in Europe. Overall survival (OS) was the most important attribute, closely followed by risk of diarrhea and hypertension, and other adverse event (AE) risks. Patients were willing to trade OS to reduce AE risks. While less important than OS and AEs, patients also preferred shorter waiting times, and one-off administration of selective internal radiation therapy and oral tablets over intravenous infusions. Although patients placed the most value on extending OS, they were willing to forego OS to avoid risk of treatment-related AEs, to maintain their quality of life.
AU - Lo,SH
AU - Sharma,R
AU - Costentin,CE
AU - Aggio,D
AU - Shergill,S
AU - Colaone,F
AU - Brennan,VK
AU - Straccia,VA
AU - Agirrezabal,I
AU - Lloyd,AJ
DO - 10.2217/fon-2021-0697
EP - 4287
PY - 2021///
SN - 1479-6694
SP - 4275
TI - Patient preferences for advanced hepatocellular carcinoma treatment: a multicountry stated preference study
T2 - Future Oncology
UR - http://dx.doi.org/10.2217/fon-2021-0697
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000677719400001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR - https://www.futuremedicine.com/doi/10.2217/fon-2021-0697
UR - http://hdl.handle.net/10044/1/91181
VL - 17
ER -